Cirrhosis splenomegaly hypersplenism
Conditions
Interventions
study group:sequential regimen
control group:One-time embolization
Sponsors
Changshu First People's Hospital, Changshu Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with complete biochemical and imaging data to support the diagnosis of cirrhosis, splenomegaly and hypersplenism; 2. Patients aged 18-80 years, and no serious systemic diseases such as heart, lung, liver and kidney; 3. Subjects without any malignant tumor or hematological diseases.
Exclusion criteria
Exclusion criteria: 1. Those patients who take nonsteroidal anti-inflammatory drugs orally for a long time, antiplatelet drugs, anticoagulants and other drugs that may cause gastrointestinal bleeding; 2. Patients with upper gastrointestinal bleeding less than 3 times a year (excluding 3 times) or with different causes of bleeding; 3. Patients who do not agree to sign informed consent, do not comply with the requirements of this study, or fail to follow up on time or lose follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypersplenism improved; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of portal hypertension complications;Occurrence of adverse reactions; | — |
Countries
China
Contacts
Public ContactXu Xiaodan
Changshu First People's Hospital, Changshu Affiliated Hospital of Soochow University
Outcome results
None listed